spliceswitch
antisens
oligonucleotid
emerg
treatment
neuromuscular
diseas
sever
spliceswitch
oligonucleotid
sso
current
undergo
clinic
trial
duchenn
muscular
dystrophi
dmd
spinal
muscular
atrophi
sma
howev
develop
system
deliv
antisens
therapeut
hamper
poor
tissu
penetr
cellular
uptak
includ
cross
bloodbrain
barrier
bbb
reach
target
central
nervou
system
cn
sma
applic
investig
abil
variou
bbbcross
peptid
cn
deliveri
spliceswitch
phosphorodiamid
morpholino
oligonucleotid
pmo
target
surviv
motor
neuron
exon
inclus
identifi
branch
deriv
wellknown
apo
peptid
pmo
conjug
capabl
exon
inclus
cn
follow
system
administr
lead
increas
level
fulllength
transcript
treatment
newborn
sma
mice
peptidepmo
ppmo
conjug
result
signific
increas
averag
lifespan
gain
weight
muscl
strength
right
reflex
system
treatment
adult
sma
mice
newli
identifi
ppmo
also
result
small
signific
increas
level
premesseng
rna
mrna
exon
inclus
cn
peripher
tissu
work
provid
proof
principl
abil
select
new
peptid
paradigm
enhanc
cn
deliveri
activ
pmo
sso
use
peptidebas
deliveri
platform
treatment
sma
potenti
extend
neuromuscular
neurodegen
diseas
pinal
muscular
atrophi
sma
inherit
motor
neuron
diseas
lead
genet
caus
infant
mortal
character
loss
lower
motor
neuron
result
progress
atrophi
voluntari
muscl
group
lead
paralysi
eventu
prematur
death
caus
delet
surviv
motor
neuron
gene
sma
patient
human
second
nearli
ident
copi
gene
major
transcript
lack
exon
due
translat
silent
ctot
transit
nucleotid
within
exon
skip
exon
premesseng
rna
mrna
splice
lead
product
truncat
margin
function
smn
protein
product
transcript
contain
exon
produc
fulllength
function
smn
protein
adequ
compens
loss
unless
high
copi
number
present
case
sever
diseas
reduc
therefor
focu
current
therapeut
strategi
increas
express
smn
protein
induct
exon
inclus
use
spliceswitch
oligonucleotid
sso
modul
premrna
splice
steric
block
mechan
provid
platform
target
diseasecaus
mutat
sever
neuromuscular
diseas
particular
duchenn
muscular
dystrophi
dmd
sma
case
dmd
phase
iii
clinic
trial
biomarin
recent
complet
util
phosphorothio
sso
target
remov
exon
exon
skip
correct
outoffram
mutat
amen
dmd
patient
unfortun
improv
clinic
measur
function
walk
test
deem
insuffici
fda
approv
drug
contrast
follow
smallscal
phase
iiiii
clinic
trial
sarepta
therapeut
phosphorodiamid
morpholino
oligonucleotid
pmo
also
target
exon
call
eteplirsen
recent
approv
clinic
use
despit
rel
modest
improv
walk
test
patient
sampl
small
treatment
sma
sso
develop
ionisbiogen
pharmaceut
use
infant
children
progress
phase
iii
clinic
trial
promis
data
openlabel
phase
ii
studi
drug
call
nusinersen
expect
approv
soon
clinic
use
howev
type
sso
abl
cross
bloodbrain
barrier
bbb
reach
target
motor
neuron
central
nervou
system
cn
henc
need
deliveri
intrathec
inject
obtain
broad
cn
distribut
recent
studi
intrathec
administr
nusinersen
isissmnrx
report
despit
great
effect
patient
develop
side
effect
headach
back
pain
postlumbar
punctur
syndrom
possibl
due
use
intrathec
deliveri
techniqu
thu
strong
impetu
explor
develop
noninvas
effici
deliveri
system
therapeut
sso
enter
brain
spinal
cord
circul
dmd
sma
treatment
reduc
dosag
need
pmo
use
dmd
high
addit
requir
improv
penetr
muscl
relev
organ
type
follow
system
deliveri
well
requir
cell
type
within
organ
despit
transduct
effici
viral
gene
deliveri
use
viral
deliveri
vehicl
limit
due
immunotox
viral
coat
protein
potenti
oncogen
effect
howev
case
neuromuscular
diseas
consider
progress
made
use
nonvir
deliveri
vector
particularli
synthet
cellpenetr
peptid
cpp
case
dmd
conjug
variou
argrich
peptid
exon
skip
pmo
given
rise
dramat
improv
level
vivo
dystrophin
product
skelet
muscl
mous
model
extend
heart
muscl
use
new
rang
peptid
known
pip
recent
studi
sma
mous
model
found
conjug
pmo
peptid
follow
intraven
deliveri
abl
direct
signific
exon
inclus
brain
spinal
cord
sma
model
mice
addit
skelet
muscl
synthet
peptid
also
shown
consider
promis
year
deliveri
cn
due
small
size
low
toxic
target
specif
abil
transcapillari
deliveri
larg
biocargo
sever
peptid
report
bbb
permeabl
either
alon
carri
biocargo
thu
parallel
recent
studi
argrich
peptid
pmo
carrier
brain
spinal
cord
sma
mous
ask
whether
possibl
identifi
peptid
type
capabl
simultan
enhanc
muscl
cell
penetr
pmo
biocargo
skelet
muscl
tissu
well
deliv
spliceswitch
pmo
cn
sma
mice
thu
screen
test
two
main
type
altern
peptidepmo
ppmo
conjug
one
case
peptid
compon
might
expect
util
receptormedi
bbb
transcytosi
mechan
well
case
cation
ppmo
might
subject
absorptivemedi
bbb
transcytosi
similar
detail
vivo
test
sma
mice
wish
exclud
peptid
pmo
conjug
lead
suffici
enhanc
cell
uptak
activ
extrem
import
obtain
addit
enhanc
bbb
cross
thu
first
use
twostag
cellular
spliceswitch
screen
gaug
cell
uptak
effici
premrna
target
abil
conjug
preliminari
screen
muscl
cell
penetr
carri
use
wellestablish
exonskip
assay
dmd
mous
mdx
muscl
cell
line
high
dynam
rang
secondstag
test
involv
induct
exon
inclus
human
sma
patientderiv
fibroblast
cell
line
sever
cellact
peptid
pass
screen
test
pmo
conjug
newborn
mous
model
sma
carri
human
transgen
measur
level
exon
inclus
intraven
inject
postnat
day
led
identif
branch
apo
ka
peptid
candid
pmo
conjug
demonstr
show
dramat
improv
lifespan
homozyg
newborn
sma
mice
median
lifespan
day
day
two
sma
mice
surviv
day
abil
branch
peptid
deliveri
exoninclud
pmo
cn
also
evalu
adult
sma
mice
intraven
administr
show
abl
deliv
pmo
cn
restor
fulllength
premrna
fmoc
protect
laamino
acid
coupl
reagent
hbtu
pybop
fmocglyohpreload
wang
resin
mmolg
obtain
merck
hohenbrunn
germani
fmoclbishomopropargylglycineoh
bpg
purchas
chiralix
nijmegen
germani
chicken
embryo
extract
cee
hors
serum
cell
cultur
obtain
sera
laboratori
intern
ltd
west
sussex
uk
ginterferon
obtain
roch
appli
scienc
penzberg
germani
highcapac
cdna
rt
kit
appli
biosystem
warrington
uk
power
sybr
green
pcr
master
mix
life
technolog
paisley
uk
primer
integr
dna
technolog
leuven
belgium
pmo
fromgen
tool
llc
philomath
lumiprob
hallandal
beach
fl
reagent
obtain
sigmaaldrich
st
loui
mo
linear
peptid
synthes
use
fmoc
chemistri
ctermin
free
carboxyl
acid
use
fmocglyohpreload
wang
resin
cem
liberti
microwav
peptid
synthes
buckingham
uk
standard
trifluoroacet
acid
tfa
labil
sidechainprotect
group
use
amino
acid
except
ly
asp
glu
protect
hydrazinelabileprotect
group
ivdd
ly
odmab
asp
glu
peptid
includ
ctermin
bpg
residu
synthes
mmol
scale
use
excess
fmocprotect
amino
acid
pybop
dipea
min
fmoclbishomopropargylglycineoh
bpg
purchas
chiralix
nijmegen
netherland
nafmocprotect
group
remov
use
piperidin
dmf
vv
min
prevent
racem
cystein
histidin
residu
coupl
min
peptid
chain
cleav
solid
support
treatment
cocktail
dodt
water
triisopropylsilan
tip
ml
min
peptid
precipit
icecold
diethyl
ether
peptid
pellet
wash
three
time
icecold
diethyl
ether
branch
br
peptid
modifi
postsynthesi
format
disulfid
bond
first
disulfid
bond
easili
form
oxid
cystein
residu
first
dissolv
linear
peptid
nh
hco
solut
ml
ph
follow
addit
mm
solut
dpd
methanol
mg
sinc
chang
retent
time
oxid
peptid
format
disulfid
bond
confirm
ellman
test
format
second
disulfid
bond
carri
simultan
remov
acmprotect
group
oxid
cystein
dissolv
acet
acid
mgml
mm
hcl
solut
vv
ad
follow
addit
iodin
eqacm
mm
solut
progress
reaction
monitor
use
reversedphas
high
perform
liquid
chromatographi
rphplc
due
slow
rate
oxid
amount
iodin
increas
eqacm
group
follow
complet
reaction
min
peptid
precipit
cold
diethyl
ether
peptid
pellet
dissolv
water
mm
ascorb
acid
solut
ad
quench
remain
trace
iodin
peptid
purifi
use
prepar
rphplc
phenomenex
column
mm
mm
use
tfabas
buffer
malditof
mass
spectrometri
abi
voyag
de
pro
use
character
peptid
use
either
acid
sinap
acid
matric
pmo
sequenc
human
inclus
target
intron
splice
silenc
region
intron
control
scrambl
sequenc
pmo
sequenc
skip
dmd
premrna
obtain
gene
tool
llc
purifi
peptid
conjug
pmo
amid
bond
free
carboxyl
group
ctermin
peptid
secondari
amino
group
pmo
peptid
dissolv
nmp
concentr
mm
pmo
dissolv
dimethyl
sulfoxid
dmso
final
concentr
mm
excess
peptid
pmo
use
peptid
activ
use
hbtu
hobt
conjug
pmo
presenc
fourfold
excess
diea
reaction
carri
h
ppmo
treat
hydrazin
eq
min
deprotect
ivdd
odmabprotect
group
purif
posit
charg
ppmo
purifi
cationexchang
column
ge
healthcar
use
mm
sodium
phosphat
buffer
ph
contain
acetonitril
buffer
nacl
ad
use
elut
ppmo
remov
excess
salt
achiev
centrifug
use
amicon
centrifug
filter
devic
ppmo
posit
charg
purifi
use
rphplc
tfa
buffer
trifluoroacet
counter
ion
remov
dissolv
lyophil
ppmo
mm
hcl
solut
filter
concentr
ml
wash
three
time
deioniz
water
remov
excess
hcl
lyophil
overal
yield
ppmo
conjug
rang
base
start
amount
pmo
determin
ultraviolet
absorb
nm
mous
mdx
myoblast
maintain
highglucos
dulbecco
modifi
eagl
medium
dmem
contain
fetal
calf
serum
cee
interferong
myoblast
differenti
myotub
exonskip
assay
previous
describ
exonskip
assay
carri
incub
myotub
appropri
concentr
ppmo
dissolv
serumfre
optimem
h
transfect
medium
replac
hors
serum
cell
incub
h
level
skip
tandem
apoepmo
branch
apo
ka
pmo
also
measur
presenc
serum
ppmo
mm
preincub
mous
serum
h
transfect
cell
total
rna
isol
mdx
cell
use
trizol
sigma
uk
rna
ng
use
carri
complementari
dna
cdna
synthesi
primari
polymeras
chain
reaction
pcr
amplif
dystrophin
dmd
transcript
use
superscript
iii
onestep
rtpcr
system
platinum
taq
dna
polymeras
invitrogen
previous
describ
primer
use
first
pcr
amplif
aattgctgag
tgtcatcc
second
pcr
carri
use
ml
first
pcr
templat
use
supertaq
polymeras
h
biotechnolog
ltd
prime
pcr
product
fraction
agaros
gel
scan
use
geldoc
imag
system
biorad
area
densiti
band
determin
use
imag
lab
softwar
biorad
rel
amount
skip
express
percentag
total
dmd
transcript
given
concentr
ppmo
conjug
data
express
meanstandard
error
mean
sem
least
three
independ
experi
mt
cell
viabil
assay
previous
describ
briefli
cell
plate
plate
treat
ppmo
rel
high
concentr
mm
level
cell
viabil
measur
use
celltit
aqueou
one
solut
reagent
promega
accord
manufactur
instruct
untreat
cell
use
control
viabil
treat
cell
express
percentag
control
human
sma
fibroblast
exon
inclus
assay
follow
screen
ppmo
conjug
mdx
cell
assay
cell
intern
exonskip
efficaci
sever
rabi
viru
glycoprotein
rvg
thr
brapo
ka
test
spliceswitch
activ
sma
patientderiv
fibroblast
cell
assay
measur
percentag
increas
level
fulllength
transcript
use
real
timepolymeras
chain
reaction
rtpcr
briefli
sma
fibroblast
cell
coriel
plate
densiti
cellsml
sixwel
plate
cell
treat
three
differ
concentr
ppmo
nmol
pcr
carri
use
twostep
protocol
total
rna
obtain
sma
patient
cell
line
extract
tri
reagent
sigmaaldrich
one
microgram
total
rna
ml
depctreat
water
ml
pmol
oligo
primer
sigmaaldrich
use
cdna
firststrand
synthesi
reaction
mixtur
incub
min
place
ice
afterward
ml
dntp
stock
solut
mm
ge
healthcar
ml
super
rtbuffer
h
biotechnolog
ltd
ml
rnasin
promega
ml
super
rt
h
biotechnolog
ltd
ml
depctreat
water
ad
reaction
mixtur
incub
min
subsequ
ml
rtpcr
product
use
templat
primari
pcr
carri
ml
volum
u
taq
dna
polymeras
h
biotechnolog
ltd
use
oligonucleotid
forward
primer
revers
primer
cycl
condit
min
min
min
final
min
cycl
pcr
product
analyz
agaros
gel
tbe
buffer
band
visual
sybr
safe
invitrogen
molecular
probe
stain
gel
document
use
geldoc
imag
system
biorad
experi
carri
biomed
scienc
unit
univers
oxford
accord
procedur
author
uk
home
offic
approv
unit
approv
board
experi
carri
use
smalik
mous
strain
tg
purpos
welfar
peptid
screen
carri
hemizygot
tgtg
pup
gener
previous
describ
litter
n
per
ppmo
inject
ppmo
nmol
ml
salin
control
litter
inject
salin
neonat
mice
euthan
day
postinject
brain
kidney
quadricep
extract
frozen
dri
ice
rna
extract
brapo
k
pmo
brapo
ka
scrambl
pmo
analyz
homozygot
pup
tgo
gener
previous
describ
pup
use
phenotyp
assess
inject
mgg
nmol
brapo
ka
pmo
brapo
ka
scrambl
pmo
smapmo
facial
vein
treat
anim
weigh
daili
observ
surviv
longev
human
endpoint
determin
mobil
weight
anim
reach
human
endpoint
euthan
rise
co
pup
also
test
hindlimb
strength
neg
geotaxi
hindlimb
strength
score
use
hindlimb
suspens
hl
test
develop
psychogen
inc
describ
standard
protocol
procedur
preclin
studi
treatnmd
hl
score
relat
posit
leg
tail
pup
suspend
hindlimb
onto
lip
test
tube
score
given
relat
weakest
phenotyp
feet
clasp
tail
given
strongest
phenotyp
leg
spread
tail
purpos
reproduc
factor
leg
pull
time
left
analysi
right
reflex
measur
place
pup
back
time
abil
right
onto
four
paw
quantit
realtim
pcr
rna
extract
harvest
tissu
revers
transcrib
use
high
capac
cdna
rt
kit
appli
biosystem
accord
manufactur
instruct
reaction
contain
mg
rna
rt
buffer
mm
dntp
mix
rt
random
primer
multiscrib
revers
transcriptas
final
volum
ml
quantit
realtim
pcr
analysi
carri
steponeplu
thermocycl
use
power
syber
green
master
mix
appli
biosystem
amplif
fulllength
total
transcript
carri
use
ng
cdna
templat
total
volum
ml
primer
use
fulllength
amplif
forward
gct
ttg
gga
agt
atg
tta
att
tca
revers
cta
tgc
cag
cat
ttc
tcc
tta
att
total
forward
gcg
atg
att
ctg
aca
ttt
gg
revers
gga
agc
tgc
agt
att
ctt
obtain
integr
dna
technolog
chang
level
fulllength
transcript
express
variou
tissu
determin
normal
total
transcript
data
analyz
use
prism
softwar
graphpad
softwar
inc
la
jolla
ca
plot
express
rel
salinetr
group
data
express
mean
sem
statist
signific
salinetr
ppmotreat
group
determin
use
student
ttest
p
valu
consid
statist
signific
tail
vein
administr
adult
mice
carri
unaffect
mice
tgtg
week
age
mice
given
weekli
dose
mgkg
bodyweight
brapo
ka
pmo
n
tissu
harvest
day
post
final
administr
agematch
control
anim
n
given
singl
salin
intraven
mlg
bodyweight
tissu
harvest
day
postadministr
protein
harvest
mg
tissu
homogen
ripa
buffer
mm
nacl
igep
sodium
deoxychol
sodium
dodecyl
sulfat
sd
mm
tri
buffer
ph
complet
mini
proteinas
inhibitor
roch
appli
scienc
protein
level
measur
bradford
assay
sigma
st
loui
mo
quantifi
use
bovin
serum
albumin
standard
thirti
mg
protein
load
onto
acrylamid
gel
protein
transfer
onto
mm
nitrocellulos
membran
millipor
probe
human
smn
protein
use
antismn
clone
smnkh
monoclon
antibodi
millipor
load
control
mous
btubulin
use
antibactin
monoclon
antibodi
sigma
dilut
odyssey
block
buffer
licor
bioscienc
lincoln
ne
primari
antibodi
detect
secondari
antibodi
irdy
goat
antimous
igg
licor
bioscienc
membran
imag
licor
odyssey
fc
imag
analyz
imag
studio
softwar
licor
bioscienc
lincoln
ne
serum
mice
administ
two
dose
day
apart
mgkg
brapo
ka
pmo
brapo
ka
scrambl
pmo
untreat
control
extract
jugular
vein
upon
harvest
day
post
final
administr
analysi
toxic
biomark
perform
clinic
patholog
laboratori
mari
lyon
center
mrc
harwel
uk
chemic
synthes
rang
peptid
tabl
analogu
endogen
peptidesprotein
design
bind
receptor
bbb
acetylcholin
receptor
achr
lowdens
lipoprotein
receptor
ldlr
lipoprotein
receptorrel
protein
apolipoprotein
receptor
apoer
transferrin
receptor
tfr
neuron
gangliosid
receptor
peptid
includ
rvg
apo
thr
addit
synthes
peptid
identifi
phage
display
screen
tgn
peptid
deriv
hsv
glycoprotein
protegrin
peptid
hydrophob
peptid
pfv
hybrid
protegrinhydrophob
peptid
peptid
also
highli
cation
might
expect
use
absorptivemedi
transcyotosi
pathway
bbb
cross
altern
addit
receptormedi
pathway
cation
charg
also
facilit
good
cell
uptak
furthermor
two
peptid
synthes
doubl
version
either
linear
tandem
peptid
tandem
apo
branch
br
peptid
branch
ly
residu
cterminu
brapo
well
mutant
brapo
ka
peptid
synthes
ctermin
carboxyl
acid
furnish
bishomopropargylglycin
bpg
residu
enabl
click
conjug
fluoresc
label
purifi
use
rphplc
eg
see
supplementari
fig
supplementari
data
avail
onlin
www
liebertpubcomnat
purif
branch
actffyggsrgkrnnfkteeyxbpgg
apo
aclrklrkrllrxbpgg
achlnilstlwkyrxbpgg
thr
acthrppmwspvwpxbpgg
achglastltrwahynalirafgggxbpgg
pfv
acpfvylixbpgg
acrrlsysrrrfxbpgg
acrrlsysrrrfpfvylixbpgg
tgn
actgnykalhphngxbpgg
pmo
conjug
cellular
assay
measur
cell
uptak
abil
vivo
test
screen
peptid
pmo
conjug
two
cellular
assay
determin
peptid
capabl
enhanc
cellular
uptak
premrna
target
pmo
first
conjug
peptid
wellvalid
dmd
pmo
sequenc
measur
spliceswitch
activ
differenti
skelet
muscl
mdx
cell
measur
level
dmd
skip
cell
assay
high
dynam
rang
thu
good
primari
screen
gener
cell
deliveri
rnatarget
abil
ppmo
conjug
show
concentrationdepend
increas
skip
fig
among
ppmo
design
bbb
receptor
target
apo
pmo
conjug
show
highest
exonskip
activ
mdx
cell
statist
greater
pmo
alon
fig
case
ppmo
peptid
compon
unknown
mode
bbb
cross
show
skip
activ
mdx
cell
higher
nake
pmo
fig
branch
linear
dimer
apo
show
significantli
higher
activ
lower
concentr
monomer
apo
pmo
fig
wherea
pmo
conjug
dimer
chimera
improv
exon
skip
activ
singl
ppmo
fig
modifi
branch
construct
brapoepmo
ka
equal
activ
exon
skip
unmodifi
counterpart
nm
mm
less
activ
counterpart
fig
case
tandem
apoepmo
branch
brapo
ka
pmo
conjug
check
serum
stabil
exon
skip
also
assess
treatment
conjug
mous
serum
exon
skip
level
decreas
significantli
ppmo
h
serum
treatment
level
remain
unalt
h
treatment
fig
demonstr
although
peptid
prone
proteolysi
serum
reason
level
spliceswitch
activ
nevertheless
maintain
measur
cytox
ppmo
show
highest
spliceswitch
activ
test
cell
viabil
human
hepatocyt
follow
incub
mm
fig
sinc
liver
accumul
well
known
ppmo
therapeut
oligonucleotid
type
compar
untreat
cell
signific
reduct
cell
viabil
seen
conjug
except
pmo
conjug
branch
tandem
dimer
apo
viabil
level
drop
contrast
k
analogu
brapo
show
significantli
less
cytotox
cell
viabil
therefor
k
analogu
use
work
test
cellular
uptak
activ
direct
relev
sma
number
select
peptid
convey
high
activ
pmo
first
round
screen
conjug
pmotarget
iss
branch
apoepmo
ka
mm
measur
preincub
ppmo
mous
serum
h
level
dmd
skip
significantli
decreas
h
remain
unchang
h
p
p
p
cf
pmo
mm
p
p
cf
pmo
mm
bbb
bloodbrain
barrier
dmd
duchenn
muscular
dystrophi
pmo
phosphorodiamid
morpholino
oligonucleotid
ppmo
peptidepmo
site
region
intron
premrna
evalu
exon
inclus
activ
sma
type
fibroblast
cell
line
level
fulllength
premrna
increas
follow
ppmo
treatment
measur
use
rtpcr
although
dynam
rang
cell
assay
larg
dmd
mdx
muscl
cell
ppmo
conjug
test
show
concentrationdepend
increas
level
fulllength
mrna
fibroblast
cell
assay
fig
wherea
untreat
cell
show
level
fulllength
premrna
ca
ssotreat
cell
show
increas
concentr
use
brapo
ka
pmo
conjug
show
highest
exon
inclus
activ
consist
result
obtain
first
round
screen
dmd
exon
skip
activ
mdx
cell
brapo
ka
peptid
conjug
scrambl
pmo
serv
neg
control
show
exon
inclus
activ
screen
assay
progress
peptid
known
bbb
receptor
target
tri
determin
whether
receptormedi
uptak
could
observ
brain
endotheli
cell
cell
known
express
expect
receptor
test
ppmo
conjug
label
fluoresc
dye
cell
uptak
measur
flow
cytometri
competit
bind
assay
absenc
presenc
excess
unlabel
peptid
data
shown
although
ppmo
test
taken
well
brain
endotheli
cell
differ
observ
cell
incub
ppmo
conjug
alon
cell
coincub
ppmo
conjug
excess
unlabel
peptid
thu
conclus
whether
receptormedi
uptak
mechan
occur
cell
could
drawn
vivo
spliceswitch
activ
ppmo
neonat
sma
mice
base
cellular
activ
data
dmd
exonskip
muscl
cell
exoninclus
assay
sma
patient
fibroblast
select
ppmo
highest
cell
activ
low
toxic
assay
vivo
chose
neonat
sma
mous
model
allow
screen
larger
number
ppmo
case
adult
mice
lower
dose
therefor
reduc
synthesi
requir
thu
neonat
sma
mice
tgtg
wtwt
tgtg
treat
ppmo
conjug
nmol
two
dose
mgkg
develop
stage
pup
treat
facial
vein
administr
effect
ppmo
increas
fulllength
premrna
determin
measur
chang
level
fulllength
premrna
rel
total
transcript
day
treatment
quantit
pcr
qpcr
fig
among
ppmo
test
brapo
ka
conjug
display
exon
inclus
activ
three
organ
test
brain
kidney
quadricep
wherea
level
exon
inclus
activ
ppmo
conjug
statist
signific
compar
salin
nake
pmotreat
group
level
fulllength
premrna
brain
measur
brapo
ka
pmo
n
higher
salinetr
n
nake
pmotreat
mice
n
brapo
ka
pmo
also
display
significantli
higher
activ
skelet
muscl
quadricep
tissu
n
well
kidney
n
fig
phenotyp
correct
neonat
sma
mice
treat
ppmo
follow
identif
brapo
ka
pmo
activ
conjug
signific
spliceswitch
activ
brain
well
skelet
muscl
effect
surviv
weight
gain
right
reflex
hindlimb
strength
newborn
sma
mice
assess
sma
mice
treat
smapmo
brapo
ka
pmo
brapo
ka
scrambledpmo
two
dose
mg
kg
nmol
brapo
ka
scrambledpmotr
mice
median
surviv
day
significantli
differ
salinetr
mice
median
surviv
day
fig
nake
smapmotr
mice
surviv
median
day
howev
brapo
ka
pmo
treatment
led
signific
increas
median
surviv
newborn
sma
mice
day
p
logrank
mantelcox
supplementari
tabl
brapo
k
pmotreat
mice
also
show
increas
weight
gain
compar
nake
pmotreat
mice
fig
hindlimb
strength
fig
right
abil
fig
also
significantli
improv
time
untreat
sma
mice
becom
progress
weaker
vivo
spliceswitch
activ
ppmo
adult
sma
mice
shown
multipl
dose
brapo
ka
pmo
signific
effect
allevi
sma
phenotyp
newborn
sma
mice
subsequ
decid
studi
effect
ppmo
restor
fulllength
transcript
smn
protein
adult
sma
mice
test
particular
cn
uptak
abil
ppmo
brapo
ka
pmo
found
restor
fulllength
cn
well
peripheri
treatment
adult
sma
mice
weekli
dose
mgkg
brapo
ka
pmo
result
signific
chang
level
vivo
screen
ppmo
conjug
target
exon
inclus
sma
mice
increas
fulllength
transcript
brain
kidney
quadricep
follow
facial
vein
inject
determin
use
realtim
revers
transcriptas
quantit
polymeras
chain
reaction
rtqpcr
branch
apo
ka
pmo
ppmo
show
signific
increas
level
fulllength
transcript
three
tissu
compar
control
salin
nake
pmo
treat
group
b
level
fulllength
transcript
newborn
sma
mice
treat
ppmo
measur
use
rtqpcr
chang
level
fulllength
transcript
express
normal
total
transcript
data
present
mean
sem
p
p
cf
salin
nake
pmotreat
group
pnd
postnat
day
sem
standard
error
mean
fulllength
transcript
kidney
three
region
spinal
cord
brain
stem
although
chang
could
detect
cerebellum
cortex
fig
addit
qpcr
test
level
smn
protein
salineand
brapo
ka
pmotreat
tissu
supplementari
fig
signific
increas
level
smn
protein
observ
kidney
unfortun
western
blot
sensit
enough
detect
signific
chang
protein
express
spinal
cord
despit
increas
level
fulllength
premrna
detect
qpcr
serum
chemistri
adult
mice
collect
two
dose
mgkg
brapo
ka
pmo
brapo
ka
scrambl
pmo
untreat
analyz
alanin
transaminas
alt
aspart
transaminas
ast
creatinin
urea
total
protein
level
within
normal
rang
fvbn
mice
supplementari
tabl
genetarget
oligonucleotid
analogu
pmo
pna
shown
great
promis
treatment
variou
neuromuscular
neurodegen
genet
diseas
case
antisens
oligonucleotid
design
modul
aberr
splice
premrna
favor
produc
therapeut
relev
rna
transcript
sso
develop
treatment
variou
cn
diseas
frontotempor
dementia
ftd
menk
diseas
huntington
diseas
amyotroph
later
sclerosi
sma
howev
poor
cellular
uptak
bbb
permeabl
roadblock
system
deliv
oligonucleotid
clinic
applic
date
vivo
studi
sso
therefor
carri
use
intracerebr
ventricular
icv
intrathec
inject
includ
sso
nusinersen
isissmn
rx
current
clinic
trial
ionisbiogen
pharmaceut
requir
multipl
intrathec
inject
sma
patient
mostli
infant
clinicaltrialgov
identifi
pmo
use
sever
clinic
preclin
studi
due
high
stabil
low
toxic
pmo
sequenc
also
known
previous
studi
porenski
et
al
singl
icv
inject
mg
pmo
newborn
mice
increas
level
fulllength
rna
transcript
brain
spinal
cord
well
smn
protein
yield
increas
surviv
day
similar
studi
zhou
et
al
use
pmo
sequenc
well
surviv
data
obtain
follow
icv
inject
mgg
compar
obtain
porenski
et
al
studi
pmo
conjug
octaguanidin
dendrim
vivomorpholino
shown
previous
effect
splice
switch
dmd
mice
howev
icv
inject
mgkg
design
exon
inclus
led
death
mice
dose
mgkg
result
hydrocephalu
system
administr
also
fail
restor
fulllength
brain
demonstr
limit
octaguanidin
dendrim
pmo
deliveri
vector
cn
contrast
argininerich
cpp
much
use
system
deliveri
pmo
cardiac
skelet
muscl
enhanc
dystrophin
express
dmd
mous
model
recent
report
use
cpp
deliveri
pmo
brain
cn
circul
prerequisit
system
applic
diseas
sma
current
studi
aim
cellular
vivo
screen
identifi
novel
peptid
activ
splice
switch
cell
muscl
sma
patient
fibroblast
system
deliveri
pmo
sso
sma
mous
model
restor
express
skelet
muscl
well
cn
sma
mous
pup
model
particularli
relev
diseas
sinc
smn
protein
requir
motor
neuron
develop
earli
postnat
stage
develop
exon
inclus
premrna
increas
smn
protein
level
lead
extens
surviv
serv
good
phenotyp
readout
initi
cell
prescreen
spliceswitch
effici
ppmo
conjug
differenti
mous
mdx
cell
fig
branch
tandem
dimer
apoepmo
identifi
particularli
activ
compar
nake
pmo
howev
subsequ
cell
viabil
evalu
fig
high
level
cytotox
observ
ppmo
perhap
due
high
number
cation
amino
acid
contrast
cytotox
significantli
reduc
replac
ly
residu
ala
brapo
ka
pmo
give
branch
peptid
less
posit
charg
spliceswitch
effici
still
maintain
ly
residu
substitut
rather
arg
due
suggest
effici
cellpenetr
abil
argcontain
cellpenetr
peptid
ly
line
dmd
exonskip
result
mdx
cell
brapo
ka
pmo
show
highest
spliceswitch
activ
screen
sma
type
fibroblast
exon
inclus
fig
establish
sma
cell
assay
lower
dynam
rang
prescreen
use
dmd
exonskip
assay
address
vivo
system
deliveri
pmo
novel
peptid
highthroughput
manner
carri
screen
ppmo
newborn
sma
mice
latest
age
conjug
could
reliabl
administ
facial
vein
conjug
test
brapo
ka
pmo
show
exon
inclus
three
organ
assess
brain
kidney
quadricep
fig
statist
signific
compar
control
salineand
nake
pmotreat
mice
besid
brapo
ka
includ
peptid
also
induc
signific
increas
level
fulllength
transcript
quadricep
organ
includ
brain
shown
previous
enhanc
vivo
brain
uptak
biocargo
dalargin
pegyl
nanoparticl
note
peptid
moder
cation
five
arg
residu
therefor
may
act
quadricep
like
cpp
peptid
also
show
high
spliceswitch
abil
mdx
muscl
cell
fig
howev
abil
brapo
ka
activ
brain
skelet
muscl
tissu
give
peptid
particular
advantag
sma
therapeut
develop
branch
arrang
peptid
also
result
slightli
serum
stabil
tandem
dimer
apo
may
provid
better
cluster
guanidinium
group
arg
bind
neg
charg
glycan
cell
surfac
endocytot
uptak
peptid
unfortun
data
could
obtain
like
mechan
transcytosi
sinc
competit
experi
brain
endotheli
cell
known
express
apo
receptor
prove
inconclus
branch
peptid
also
arg
rich
thu
whether
receptormedi
absorpt
transcytosi
occur
across
bbb
brapo
ka
pmo
combin
two
mechan
remain
unclear
also
possibl
uptak
bloodcerebrospin
fluid
barrier
ventricular
system
howev
full
understand
exact
mechan
transcytosi
peptid
vivo
challeng
establish
well
beyond
scope
current
articl
evalu
brapo
ka
pmo
rescu
sma
phenotyp
result
signific
extens
median
surviv
sma
mous
pup
day
two
mice
surviv
day
respect
brapo
ka
pmotreat
mice
also
show
increas
weight
gain
higher
muscl
strength
compar
nake
pmotreat
mice
well
improv
right
abil
compar
salin
brapo
ka
scrambledpmotr
mice
pup
test
sinc
untreat
nakedpmo
brapo
ka
scrambledpmotr
pup
surviv
beyond
test
brapo
ka
pmotreat
pup
show
signific
sustain
surviv
weight
gain
muscl
strength
right
reflex
particularli
interest
observ
effect
brapo
ka
pmo
increas
level
fulllength
smn
protein
adult
sma
mice
bbb
much
less
permeabl
six
weekli
intraven
dose
brapo
ka
pmo
mgkg
result
increas
level
fulllength
premrna
cn
well
skelet
muscl
kidney
unfortun
chang
smn
protein
level
could
determin
lack
sensit
western
blot
assay
supplementari
fig
nevertheless
exon
inclus
result
show
brapo
ka
capabl
deliv
conjug
pmo
skelet
muscl
cn
great
signific
treatment
sma
current
unclear
cn
apo
peptid
abl
deliv
pmo
futur
studi
conduct
elucid
inform
applic
pmo
deliveri
smn
protein
ubiquit
express
highli
conserv
across
speci
express
peak
develop
lower
motor
neuron
thought
primari
target
sma
vivo
evid
stage
neuron
cell
uptak
brainspin
cord
ppmo
evid
uptak
present
nake
pmo
inject
intrathec
sma
mous
brain
show
substanti
mous
surviv
enhanc
experi
requir
separ
studi
need
signific
quantiti
label
ppmo
thu
whether
exon
inclus
seen
adult
sma
mice
brain
spinal
cord
system
brapo
ka
pmo
inject
occur
neuron
glial
cell
endotheli
cell
combin
current
determin
extens
surviv
seen
sever
sma
mice
may
suggest
least
exon
inclus
could
occur
neuron
increas
number
clinic
experiment
studi
emerg
indic
involv
peripher
organ
pathogenesi
sma
therefor
bodywid
increas
fulllength
premrna
exon
inclus
demonstr
result
therefor
smn
protein
desir
cn
current
clinic
trial
nusinersen
carri
use
multipl
intrathec
inject
sever
drawback
includ
complic
relat
lumbar
punctur
poor
cn
distribut
sso
lack
therapeut
benefit
peripher
patholog
compon
diseas
recent
studi
sma
mice
also
shown
subcutan
administr
sever
low
dose
pmo
greater
effect
increas
averag
surviv
sma
mice
singl
highdos
icv
bolu
inject
studi
howev
shown
greater
benefit
use
ppmo
conjug
compar
nake
pmo
oligonucleotid
signific
allevi
sma
phenotyp
result
compar
activ
spinal
cord
adult
mice
previou
howev
peptid
longer
contain
higher
number
posit
charg
arg
residu
initi
indic
may
suffici
favor
therapeut
index
clinic
develop
godfrey
et
al
unpublish
result
clear
current
studi
novel
peptid
discover
beyond
pip
seri
brapo
ka
pmo
first
new
exampl
sma
applic
ongo
work
aim
carri
detail
vivo
studi
parallel
activ
toxicolog
identifi
novel
peptid
accept
therapeut
index
may
suitabl
lead
drug
develop
howev
believ
current
work
pave
way
develop
peptidebas
system
deliveri
platform
skelet
tissu
cn
sso
treatment
sma
perhap
might
extend
neuromuscular
neurodegen
diseas
